NEW YORK (TheStreet) -- Amgen
(AMGN) shares are down -5.26% to $113.11 in trading on Wednesday following the release of the company's first quarter 2014 earnings report.
The biotech company posted net income of $1.44 billion, or $1.87 per share, missing analysts consensus estimates by 7 cents.
Year over year quarterly revenue was up 7% to $4.52 billion, missing analysts estimates of $4.76 billion.
The company maintained full year guidance of revenue between $19.2 billion - $19.6 billion, or $7.90 - $8.20 per share.
Must Read: Warren Buffett's 10 Favorite Stocks
SELL NOW: If you own any of the 900 stocks that TheStreet Quant Ratings has identified as a 'Sell'...you could potentially lose EVERYTHING in the next 6-12 months. Learn more.
STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts